Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0474 has been discontinued.
View all Non-selective Adrenergic α Receptors products.Dihydroergocristine mesylate is a 5-HT receptor antagonist; partial agonist at adrenergic and dopaminergic receptors.
分子量 | 707.84 |
公式 | C35H41N5O5.CH3SO3H |
储存 | Store at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 24730-10-7 |
PubChem ID | 444034 |
InChI Key | SPXACGZWWVIDGR-SPZWACKZSA-N |
Smiles | CS(=O)(O)=O.[H][C@]4([C@@]([H])3C[C@@H]([C@@](N[C@@]5([C@H](C)C)C(N([C@@]([H])(CC8=CC=CC=C8)C(N7[C@]([H])6CCC7)=O)[C@@]6(O)O5)=O)=O)CN4C)CC1=CNC2=C1C3=CC=C2 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Drago (1988) Dihydroergocristine and memory alterations of aged male rats. Pharmacol.Biochem.Behav. 30 961 PMID: 3147464
关键词: Dihydroergocristine mesylate, Dihydroergocristine mesylate supplier, Partial, α-adrenoceptors, α-adrenoceptor, alpha-adrenoceptors, agonists, Non-Selective, dopamine, receptors, partial, α-adrenergic, alpha-adrenergic, a-adrenergic, 5-HT, antagonists, dopaminergic, D2-like, 5-Hydroxytryptamine, Serotonin, 5-HT3, Non-selective, Adrenergic, Alpha, Receptors, Dopamine, 0474, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。
目前没有 Dihydroergocristine mesylate 的引用文献。
目前没有该产品的评论。 Be the first to review Dihydroergocristine mesylate and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.